AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case.

10/02/2026, 1:37 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud related to its February 2025 IPO and subsequent period through May 2026. The complaint claims the company made materially false and misleading statements about the safety and prospects of its drug candidate ARD-101, and that offering documents were negligently prepared. Investors who purchased shares during the class period are encouraged to join the lawsuit.

10/02/2026, 12:00 PM • GlobeNewswire

AARDVARK DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. (AARD) of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, causing investor damages when the truth entered the market. The firm is also investigating claims related to Hyliion Holdings Corp. (HYLN) and FLOW cryptocurrency.

09/28/2026, 2:54 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging that offering documents contained false statements and that the company made materially misleading statements about the safety and prospects of its drug ARD-101. The lawsuit covers investors who purchased securities during the IPO on February 13, 2025, and through May 14, 2026. The lead plaintiff deadline is October 13, 2026.

09/25/2026, 12:00 PM • GlobeNewswire

מועד אחרון לתביעה ייצוגית נגד AARDVARK: רוזן, יועץ למשקיעים מיומן, קורא למשקיעי Aardvark Therapeutics, Inc. לשכור ייצוג משפטי לקראת מועד חשוב בתביעה ייצוגית בניירות הערך – AARD

The Rosen Law Firm announced a securities class action lawsuit against Aardvark Therapeutics, Inc. (AARD) for allegedly making false and misleading statements regarding the safety profile of its drug ARD-101 and overstating its clinical, regulatory, and commercial prospects. The lawsuit covers investors who purchased securities between February 13, 2025 (IPO date) and May 14, 2026. The deadline to file a claim is October 13, 2026.

09/22/2026, 10:05 PM • GlobeNewswire

Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors who suffered losses are urged to file lead plaintiff motions by October 13, 2026.

09/21/2026, 2:55 PM • GlobeNewswire

AARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is reminding investors in Aardvark Therapeutics (AARD), UWM Holdings (UWMC), and ARS Pharmaceuticals (SPRY) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made materially false statements and failed to disclose material adverse facts about their businesses, with Aardvark specifically accused of overstating the safety and commercial prospects of its ARD-101 drug candidate.

09/18/2026, 9:39 PM • GlobeNewswire

Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws

Law firm Lowey Dannenberg is investigating Aardvark Therapeutics for potential federal securities violations related to its lead drug ARD-101. The company paused its Phase 3 trial in February 2026 due to cardiac safety concerns and faced an FDA clinical hold in May 2026, causing significant stock price declines and shareholder losses.

09/18/2026, 10:55 AM • GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is urging investors in Aardvark Therapeutics (AARD) to join a securities class action lawsuit with an October 13, 2026 deadline for lead plaintiff claims. The lawsuit alleges that defendants made materially false statements about the safety and prospects of their drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

09/08/2026, 9:27 PM • GlobeNewswire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is urging investors who purchased Aardvark Therapeutics securities during its IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 to join a securities class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements about the safety and prospects of ARD-101, with an October 13, 2026 deadline to serve as lead plaintiff.

09/05/2026, 12:34 PM • GlobeNewswire

Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors are urged to file lead plaintiff motions by October 13, 2026.

09/01/2026, 4:00 PM • GlobeNewswire

ROSEN, A LONGSTANDING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

08/30/2026, 7:07 PM • GlobeNewswire

Important Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and Hub Group, Inc. (NASDAQ: HUBG); Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office announced investigations into shareholder claims against four companies: Aardvark Therapeutics for allegedly misleading statements about drug safety leading to 56% stock decline; Flotek Industries for misrepresentations regarding a terminated Puerto Rico power project; GoDaddy for failing to disclose impact of promotional pricing on bookings; and Hub Group for material financial statement misstatements. Long-term shareholders may pursue corporate reforms and compensation.

08/27/2026, 8:50 AM • GlobeNewswire

Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline

Hagens Berman has filed a securities class action lawsuit against Aardvark Therapeutics, alleging the company made materially false statements about the safety of its lead drug candidate ARD-101. The lawsuit covers investors who purchased stock during the IPO on February 13, 2025, through May 14, 2026. Aardvark voluntarily paused its Phase 3 HERO trial in February 2026 after discovering reversible cardiac observations, causing a 56% stock decline. The FDA subsequently placed a full clinical hold on ARD-101 in May 2026, resulting in an additional 32.1% stock drop. The lead plaintiff deadline is October 13, 2026.

08/25/2026, 6:55 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

Pomerantz LLP is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, and a subsequent FDA clinical hold placed on its ARD-101 drug in May 2026. The stock declined 56.2% following the initial announcement and an additional 32.1% after the FDA clinical hold.

05/26/2026, 4:58 PM • GlobeNewswire